Abstract 311P
Background
Thyroid cancer is the most common endocrine-related malignancy in the Philippines. It ranks seventh overall based on the latest Department of Health statistics. Its incidence increases every year, noted especially in females and in the reproductive age group. This study determined the incidence and the profile of all thyroid carcinomas encountered in a tertiary teaching hospital in the Philippines.
Methods
Data were collected from the University of Santo Tomas Hospital in 2015 to 2018 from different specialties, including the Pathology Department. All information gathered were kept confidential in respect to the data privacy act.
Results
A total of 1618 thyroid specimens were sent for histopathologic examination from 2015-2018 and 35.6% (n = 576) of these were malignant. Fine needle aspiration was the most frequent form of biopsy done. Eight hundred eighty patients underwent thyroidectomy and 43% (n = 378) of them had malignancy based on final histopathology. Eighty one percent (81%) were females and 19% were males. The most common type of malignancy was papillary thyroid carcinoma (74.6%), followed by papillary microcarcinoma (18.4%), follicular carcinoma (4.8%), anaplastic carcinoma (0.7%), squamous cell (0.7%) and poorly differentiated carcinoma (0.9%). The most frequent subtype of papillary carcinoma seen was the conventional type (31.7%). Majority of the patients had no extrathyroidal extension (41%), no lymphovascular invasion (38%), had clear margins (70%) and had no lymph node involvement (21%). Of the patients diagnosed with papillary and follicular carcinoma and papillary microcarcinoma, 30% underwent RAI in the same institution. There were 17 patients who underwent radiation therapy, mostly for palliative intent because of RAI-refractory disease. There was one case who underwent concurrent chemoradiation for anaplastic thyroid carcinoma.
Conclusions
This study showed that one-third of thyroid specimens received in the institution turned out to be malignant, with papillary carcinoma still the most frequent type. Total thyroidectomy is the most common form of curative surgery done.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract